CA2157874CCA002157874ACA2157874ACA2157874CCA 2157874 CCA2157874 CCA 2157874CCA 002157874 ACA002157874 ACA 002157874ACA 2157874 ACA2157874 ACA 2157874ACA 2157874 CCA2157874 CCA 2157874C
Authority
CA
Canada
Prior art keywords
gly
antibody
hiv
ser
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute KaketsukenfiledCriticalChemo Sero Therapeutic Research Institute Kaketsuken
Priority claimed from PCT/JP1994/000371external-prioritypatent/WO1994020632A1/fr
Publication of CA2157874A1publicationCriticalpatent/CA2157874A1/fr
Application grantedgrantedCritical
Publication of CA2157874CpublicationCriticalpatent/CA2157874C/fr
Anticorps diriges contre un complexe de cd4 et d'un domaine de recepteurs des chemokines, et leur utilisation pour lutter contre les infections a vih
Fragments de gènes codant pour la région variable d'un anticorps anti-HIV, anticorps chimériques anti-HIV exprimés lors de leur utilisation et procédé pour leur préparation
Anticorps monoclonaux contre l'hiv permettant la neutralisation de ce virus et/ou l'obtention d'une cytotoxicite dependant de l'anticorps